• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

    Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

  2. Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced ...

    Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO

  3. Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced ...

    Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

  4. Exelixis's stock surges after positive results from trial of kidney cancer treatment

    Exelixis's stock surges after positive results from trial of kidney cancer treatment

  5. Global Pre-harvest Equipment Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: AGCO, Toro Company, DEERE & Company - Research and Markets

    Global Pre-harvest Equipment Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: AGCO, Toro Company, DEERE & Company - Research and Markets

  6. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  7. Global Bladder Cancer Pipeline Report 2016 - Review of 94 Companies & Drug Profiles - Research and Markets

    Global Bladder Cancer Pipeline Report 2016 - Review of 94 Companies & Drug Profiles - Research and Markets

  8. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  9. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

  10. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.